Printer Friendly

Endovasc Receives Notice of Allowance for U.S. Patent Protecting Its Muscle Mass Technology.

HOUSTON -- Endovasc Inc. (OTCBB:EVSC, OTC: EVSD), today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office for its pending patent application entitled "Development of Muscle Mass in a Mammal". The patent covers the use of the Company's non-steroidal supplement technology for muscle cell recruiting and accelerated bodybuilding and strengthens Endovasc's nutraceutical intellectual property portfolio currently incorporated in the Endothil-CR product marketed by Basic Research.

"This patent adds a new layer to our Company's broad intellectual property portfolio and demonstrates Endovasc's innovation in the field of nutraceuticals. We are committed to commercializing our pipeline of nutraceutical products. Patent protection such as this is critical for ensuring Endothil-CR's exclusivity in the marketplace," said Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer.

Endovasc's wholly owned subsidiary, Nutraceutical Development Corporation (NDC), licensed the technology to Basic Research to develop and market a non-steroid supplement which utilizes the Company's muscle mass technology. Endothil-CR is currently available at GNC stores nationwide or on the World Wide Web at

About Endovasc, Inc.

Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation.

For more information about Endovasc, please visit

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 7, 2006
Previous Article:Gastar Exploration Ltd. Provides Operational Update-Latest Well Results.
Next Article:Network Engines to Present at America's Growth Capital Information Security and Data Center Conference on February 13th.

Related Articles
Endovasc Ltd. Inc. Announces New Patent for Preventing Heart Stent Reclosure and Garners Prestigious Scientific Award in Angiology.
Endovasc Ltd. Inc. Announces Filing of Two New Patents.
Endovasc Ltd. Inc. Announces U.S. Patent Office Notice of Allowance for Surface Coating Technology; Endovasc Expands Its Drug Delivery Technology...
Endovasc Signs a Development and Collaboration Agreement With One Of The Largest Chemical Companies in Asia.
Nissan and Endovasc Team Up To Deliver Liprostin - New Potential Blockbuster Treatment for Cardiovascular Disease; First Human Patients Could Be...
Endovasc Announces Results from Annual Shareholder Meeting.
Endovasc Adds Additional Member to Advisory Committee.
Endovasc Expands on Annual Meeting Agenda.
Endovasc Receives Issue Notification for U.S. Patent Protecting its Muscle Mass Technology.
Endovasc Receives US Patent Protecting Its Muscle Mass Technology.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters